-- 木曜午後遅く、金融株は上昇し、ニューヨーク証券取引所金融指数は1.3%、ステート・ストリート金融セレクト・セクターSPDR ETF（XLF）は0.5%上昇した。 フィラデルフィア住宅指数は1.6%上昇し、ステート・ストリート不動産セレクト・セクターSPDR ETF（XLRE）は1.5%上昇した。 ビットコイン（BTC-USD）は0.9%上昇し76,409ドルとなり、米国10年債利回りは2.8ベーシスポイント低下して4.39%となった。 企業ニュースでは、アバロンベイ・コミュニティーズ（AVB）とエクイティ・レジデンシャル（EQR）が合併の可能性について協議を行ったとブルームバーグが報じた。実現すれば、不動産業界史上最大級の取引となる。アバロンベイの株価は1.1%下落し、エクイティ・レジデンシャルの株価もわずかに下落した。
Related Articles
Mining & Metals
Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share
$AEM.TO
Treasury
TD Bank Group Issues 150 Million Swiss francs Green Bond
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
$TD$TD.TO
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN